Page last updated: 2024-11-04

sulfasalazine and Chylopericardium

sulfasalazine has been researched along with Chylopericardium in 2 studies

Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.

Research Excerpts

ExcerptRelevanceReference
" Pericarditis as a side effect induced by sulfasalazine or 5-aminosalicylic acid, drugs used in the therapy of these diseases, was first described only 7 years ago."2.39[Pericarditis in chronic inflammatory bowel disease: underlying disease or side effects of therapy? Clinical problem solving]. ( Krähenbühl, S; Kupferschmidt, H; Langenegger, T, 1996)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gupta, R1
Hennebry, TA1
Kinasewitz, GT1
Kupferschmidt, H1
Langenegger, T1
Krähenbühl, S1

Reviews

1 review available for sulfasalazine and Chylopericardium

ArticleYear
[Pericarditis in chronic inflammatory bowel disease: underlying disease or side effects of therapy? Clinical problem solving].
    Schweizerische medizinische Wochenschrift, 1996, Dec-14, Volume: 126, Issue:50

    Topics: Adult; Crohn Disease; Drug Combinations; Female; Glucosamine; Humans; Male; Myocarditis; Pericardial

1996

Other Studies

1 other study available for sulfasalazine and Chylopericardium

ArticleYear
Pleuropericardial effusion after 37 years of sulfasalazine therapy.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2012, Volume: 13, Issue:8

    Topics: Crohn Disease; Drug Administration Schedule; Gastrointestinal Agents; Humans; Male; Middle Aged; Per

2012